Finland · Delayed Price · Currency is EUR Revenio Group Oyj Earnings Call Transcripts
Fiscal Year 2026
-
Q1 saw 8.4% FX-adjusted sales growth, strong U.S. and Europe performance, but lower operating profit due to Visionix transaction costs. The Visionix acquisition expands the addressable market and product portfolio, with significant synergies and a rights issue planned for H2.
-
The merger creates a leading ophthalmic diagnostics company with a EUR 2.5 billion accessible market, targeting EUR 20 million in synergies and 25% EBITDA margin by 2028-2029. Integration is structured for rapid synergy capture, with strong shareholder and leadership commitment.
Fiscal Year 2025
-
Q4 and full-year 2025 saw strong sales growth, especially in the US and EMEA, with robust cash flow and expanding screening solutions. 2026 guidance projects 8%-15% net sales growth, with profitability supported by price increases and ongoing R&D, despite tariff and clinical trial cost headwinds.
-
Q3 delivered 8.1% sales growth and 9.1% higher operating profit, driven by strong European and U.S. demand for screening solutions. Guidance is unchanged, with Q4 expected to be the strongest quarter. APAC lagged due to currency headwinds, while new product launches and M&A activity continued.
-
Q2 saw 4.2% reported sales growth (7.2% currency-adjusted), with all regions and product categories contributing. Gross margin exceeded 70%, and adjusted operating profit rose ~10% in Q2. Tariff impacts are being managed with planned price increases as inventory runs out.
-
Q1 2025 saw robust organic growth in sales and profitability, with net sales up 10.5% and EBIT margin at 25.4%. All regions and product lines contributed, supported by new product launches and regulatory approvals. Tariff and FX risks are being managed through price increases and natural hedging.
Fiscal Year 2024
-
Q4 and full-year 2024 saw strong sales growth, robust profitability, and record cash flow, driven by new product launches and recurring revenue. Guidance for 2025 anticipates 6%-15% sales growth, with profitability remaining strong despite geopolitical and regulatory risks.
-
Q3 saw 8.9% net sales growth (15.1% FX-adjusted), strong product launches, and robust performance in imaging and tonometer segments. FX headwinds and higher marketing costs impacted margins, but full-year sales are expected to surpass EUR 100 million.
-
Q2 net sales grew 14.2% year-over-year, with strong performance in fundus imaging and tonometers. Profitability and cash flow improved, and guidance for 5%-10% annual sales growth is maintained. Clinical trial costs and a contingent liability remain key uncertainties.